RC-01 represents a new class of antibiotics in development for the treatment of serious antibiotic-resistant infections
MENLO PARK, CA, USA I April 01, 2019 I Recida Therapeutics, Inc. announced today the initiation of a Phase I trial for RC-01, a novel LpxC inhibitor. The trial is being conducted in the United States and is evaluating the safety, tolerability and pharmacokinetics of RC-01 in healthy subjects after single or multiple-dose intravenous administration. CARB-X has provided the funding to support this Phase I trial.
RC-01 displays highly potent inhibitory activity against the bacterial enzyme LpxC, with an IC50 at subnanomolar levels. RC-01 has potent activity against gram-negative bacteria, including multidrug-resistant Enterobacteriaceae, Pseudomonas aeruginosa and Acinetobacter baumannii which represent an urgent unmet medical need. RC-01 has a favorable drug-metabolism-pharmacokinetic profile and was well tolerated in preclinical toxicology studies. None of the toxicities encountered with previous LpxC inhibitors was observed with RC-01. Both in vitro and animal in vivo efficacy and safety data support its clinical development as a potential human therapeutic agent for the treatment of serious bacterial infections caused by gram-negative pathogens in the hospital setting.
“Despite the emergence of significant antibiotic resistance, no truly new class of anti-gram-negative antibiotic has been successfully developed in the last 65 years,” said James Ge, MD, PhD, President and CEO of Recida. “With its novel mode of action, RC-01, if successfully developed, may provide an attractive option for physicians to treat serious and life-threatening conditions caused by multidrug-resistant pathogens. We are very excited about the potential to demonstrate the broad potential of this new antibiotic candidate in the clinic.”
About Recida Therapeutics
Recida Therapeutics is a clinical-stage biotechnology company focused on developing first-in-class anti-infective medicines for the treatment of multidrug-resistant infections. The company is currently advancing its novel LpxC inhibitor, RC-01, in a Phase I clinical trial. Recida is led by an experienced team of pharmaceutical and anti-infectives executives seeking to improve outcomes for patients with multidrug-resistant and other difficult-to-treat infections. Recida is located in Menlo Park, CA. www.recidatherapeutics.com
SOURCE: Recida Therapeutics
Post Views: 21
RC-01 represents a new class of antibiotics in development for the treatment of serious antibiotic-resistant infections
MENLO PARK, CA, USA I April 01, 2019 I Recida Therapeutics, Inc. announced today the initiation of a Phase I trial for RC-01, a novel LpxC inhibitor. The trial is being conducted in the United States and is evaluating the safety, tolerability and pharmacokinetics of RC-01 in healthy subjects after single or multiple-dose intravenous administration. CARB-X has provided the funding to support this Phase I trial.
RC-01 displays highly potent inhibitory activity against the bacterial enzyme LpxC, with an IC50 at subnanomolar levels. RC-01 has potent activity against gram-negative bacteria, including multidrug-resistant Enterobacteriaceae, Pseudomonas aeruginosa and Acinetobacter baumannii which represent an urgent unmet medical need. RC-01 has a favorable drug-metabolism-pharmacokinetic profile and was well tolerated in preclinical toxicology studies. None of the toxicities encountered with previous LpxC inhibitors was observed with RC-01. Both in vitro and animal in vivo efficacy and safety data support its clinical development as a potential human therapeutic agent for the treatment of serious bacterial infections caused by gram-negative pathogens in the hospital setting.
“Despite the emergence of significant antibiotic resistance, no truly new class of anti-gram-negative antibiotic has been successfully developed in the last 65 years,” said James Ge, MD, PhD, President and CEO of Recida. “With its novel mode of action, RC-01, if successfully developed, may provide an attractive option for physicians to treat serious and life-threatening conditions caused by multidrug-resistant pathogens. We are very excited about the potential to demonstrate the broad potential of this new antibiotic candidate in the clinic.”
About Recida Therapeutics
Recida Therapeutics is a clinical-stage biotechnology company focused on developing first-in-class anti-infective medicines for the treatment of multidrug-resistant infections. The company is currently advancing its novel LpxC inhibitor, RC-01, in a Phase I clinical trial. Recida is led by an experienced team of pharmaceutical and anti-infectives executives seeking to improve outcomes for patients with multidrug-resistant and other difficult-to-treat infections. Recida is located in Menlo Park, CA. www.recidatherapeutics.com
SOURCE: Recida Therapeutics
Post Views: 21
